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Dear Editor, 
ulcerative colitis (UC) is an inflammatory bowel disease associated with a variety of ex-
traintestinal manifestations (EIMs) that may produce greater morbidity than the underlying in-
testinal disease and may even be the initial presenting symptoms. An arthritis affecting the
spine and/or peripheral joints has been considered the most common EIM of UC. It is charac-
terized by the absence of serum rheumatoid factor, the peripheral and axial form occurring in
about 10-23% and about 10-15%, respectively1-3. Articular and musculoskeletal manifestations
in UC patients are included in the spondyloarthropathies (SpAs) that are a group of seronega-
tive autoimmune related disorders with common characteristics including: ankylosing spondyli-
tis, reactive arthritis, psoriatic arthritis, inflammatory bowel disease, some forms of juvenile
arthritis and acute anterior uveitis4.
Evidence coming from many studies in genetically susceptible animal models of colitis sug-
gests the crucial role of enteric flora in activating the immune system against bacterial antigens
and contemporary against colonic mucosa on the basis of an antigenic cross-reactivity (“antigen
mimicry”). The sharing of these colonic antigens by joints, associated with a genetic susceptibility,
would lead to an immune attack against these sites5,6. Several studies in animal models of experi-
mental arthritis have demonstrated the beneficial effects of probiotics, in particular Lactobacillus
species, on articular inflammation7-10. Preliminary results suggest that a probiotic mixture (VSL#3)
may be an alternative treatment for arthralgia in patients with inflammatory bowel dis-
ease11. Nevertheless, a recent internet-based randomized controlled trial in patients with SpA has
showed no statistical or clinical significant improvement with the use of probiotics12.
We performed an open-label, non-controlled study to determine if an association of probi-
otics, Lactobacillus Acidophilus (LA) and Lactobacillus Salivarius (LS), could improve SpA in pa-
tients with quiescent UC. Eighteen patients (10:8=F:M, mean age 49 years) with quiescent UC
and active SpA received an open label association of LA and LS, two billions bacteria daily in
two divided doses for four weeks. The clinical parameters evaluated included Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI), assessing disease activity, Bath Ankylosing
Spondylitis Functional Index (BASFI), assessing patientʼs functional limitations and visual ana-
logue scale (VAS), assessing subjective pain perception. Laboratory parameters evaluated in-
cluded C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). CRP was measured
by a highly sensitive turbidimetric method (normal value <5 mg/L). ESR was assessed using a
quantitative capillary photometry-based technology. At baseline and at the end of the study
mean ± standard deviation (SD) values were calculated. Data were analyzed using Studentʼs t-
test (p<0.05 was considered significant). At baseline UC was quiescent according to UC Dis-
ease Activity Index (UCDAI), activity of SpA was documented by BASDAI score ≥4.
At the end of the study a significant reduction of BASDAI score (5.8 ± 1.5 vs 4 ± 1.8,
p<0.05) and VAS score (58.1 ± 16.8 vs 41.5 ± 14.3, p<0.05) was seen. No significant reduc-
tion of BASFI score (33.6 ± 10 vs 28.6 ± 6.3, p=0.08), CRP (25.2 ± 11 vs 19.8 ± 6.4, p=0.08)
and ESR (28 ± 11.6 vs 22.5 ± 7.1, p= 0.1) was evidenced (Table I). During the study no one of
the patients had a relapse of UC or relevant adverse effects.
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Table I. Mean ± Standard Deviation (SD) Values at baseline and at the end of the study. BASDAI, Bath Ankylosing
Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; VAS, visual analogue scale; CRP,
C-reactive protein; ESR, erythrocyte sedimentation rate; NS, not significant.
Baseline End p
BASDAI Score 5.8 ± 1.5 4 ± 1.8 < 0.05 
BASFI Score 33.6 ± 10 28.6 ± 6.3 NS
VAS Score 58.1 ± 16.8 41.5 ± 14.3 < 0.05 
CRP (mg/L) 25.2 ± 11 19.8 ± 6.4 NS
ESR (mm/hr) 28 ± 11.6 22.5 ± 7.1 NS
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These preliminary data suggest that the association of LA and LS determines a significant
reduction in SpA activity and in patientʼs perception of pain. Moreover, these bacteria donʼt in-
duce relapse of intestinal disease as non-steroidal anti-inflammatory drugs (NSAIDs) can do13.
We believe that these probiotics may give a contribute in the management of SpA in patients
with UC. However, controlled randomized clinical trials are necessary to confirm these results.  
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